Moderna - Not Your Hot-Tip-From-Your-Brother-In-Law Biotech Stock

7 Best Biotech Stocks To Add together to Your Portfolio in 2022

What Are They
Best Ones To Buy

Kkolosov / iStock.com

Biotech stocks accept a reputation as a moderate- to high-risk investment. That's considering many of these companies spend a fortune on research and development with no guarantee their products volition ever reach the market.

Many biotech stocks tend to underperform compared to the rest of the Nasdaq Composite Index, a market cap-weighted index predominantly focused on technology.

However, if you take a fairly high take chances-tolerance, a bear market represents a skilful time to take a run a risk on some stocks in the biotech industry. Stock prices are low, which means a potential for higher returns if yous choose the right companies.

Which might pb yous to the question of: What are the best biotech stocks to buy?

What Are Biotechnology Stocks?

Biotechnology combines biology and engineering to manufacture products or technology — most oft, pharmaceuticals, lab equipment or diagnostic tools — designed to prolong human life while, ideally, improving its quality.

Biotechnology stocks are the stock options that aid fund biotech companies. Many biotech companies fly under the radar of consumers or retail investors. That's because in one case they develop new drug technology, they sell information technology to a pharmaceutical visitor who can mass produce the medicine or treatments. One notable exception is the biotech firm Moderna, which played an instrumental office in the evolution of one of the first Covid-nineteen vaccines.

What Are the Best Biotech Stocks To Buy?

Some of the biotech stocks on this listing are not household names. But most have tremendous revenue potential with strong drug developments in various stages of development and successful drugs already bachelor today.

Biogen

Every bit the first biotech stock that Warren Buffett ever invested in dorsum in 2019, Biogen holds promise today for investors with a buy-and-concord mentality and high chance tolerance.

There is a lot of volatility in the company recently, with its Alzheimer's drug Aduhelm showing great hope but is merely being prescribed in specific approved trials. The Centers for Medicare & Medicaid Services essentially cut off access to the drug to Medicare beneficiaries, even after the Food and Drug Administration rushed blessing of the treatment.

All the same, bad news surrounding Aduhelm may accept been broiled into the stock'southward value, which is why the stock didn't plummet upon release of the news.

In mid-July 2022, the stock sits at $214, down nigh 40% in the past year and closer to its 52-week low of $187 than its one-year high of $358.

Pros:

Solid fundamentals
Trading near its one-yr depression
Promising Alzheimer's treatment received quick FDA approval

Cons:

Highly volatile
Aduhelm not approved for Medicare patients

BioMarin

BioMarin has recently had a cord of good news resulting in predictions of fifteen% revenue growth this year and 30% for 2023. The $xv billion company specializes in pioneering treatments for rare genetic disorders and already has many drugs on the market.

MarketBeat gives BioMarin a moderate "buy" rating, with 11 Wall Street analysts issuing a "buy" rating and three issuing a "hold."

Pros:

Outperforming S&P 500 all year
xxx% growth rate predicted for 2023

Cons:

Niche products without a large market place
Not a short-term investment

Amgen

Amgen is best known for Neulasta, a drug that reduces infection hazard in chemotherapy patients, Enbrel for inflammatory diseases and Prolia for osteoporosis. With this trilogy of successful drugs already on the marketplace, the $26 billion biopharmaceutical company has solid fundamentals and steady income. In early June 2022, The FDA canonical Amgen's rheumatoid arthritis treatment, RIABNI.

10 out of 25 Wall Street analysts covering Amgen give it a "buy" or "stiff buy" rating, according to StockNews.com. All the same, MarketBeat analysts are giving information technology a concord rating, believing this stock hasn't seen its peak nonetheless.

Pros:

Successful drugs for mutual diseases already on the market
New R.A. handling just gained FDA approval
Pays dividend of 3.i%

Cons:

Price hovering near 52-week high
Many analysts give it a hold rating

CRISPR Therapeutics

CRISPR Therapeutics takes a unique approach to drug development for the treatment of serious diseases through factor editing. The company is developing promising treatments for diseases such every bit cystic fibrosis, Alzheimer's, Parkinson'south, hemophilia, Tay-Sachs and more.

The biotech firms financial future is also promising, according to investors and analysts. MarketBeat gives CRISPR stock a "moderate buy" rating. In June 2022, U.S. News & Earth Report listed CRISPR as one of seven gene-editing stocks to buy this summer.

Pros:

Promising treatments for mutual hereditary diseases
Closer to 52-week high than 52-week low

Cons:

Not a practiced buy for adventure-averse investors
Not a short-term buy

Exelixis

Exelixis is a company focused on cancer treatments or, as its website states, a company that strives "to develop effective, tolerable and durable treatments to assist patients with cancer thrive. To date, the company has medicines bachelor to care for kidney, liver and thyroid cancers along with advanced melanoma treatments.

10 Wall Street analysts are calling Exelixis a "buy" or a "potent buy" for 2022, according to WallStreetZen.com. No analysts have given it a "hold" or "sell" rating. The company shows an annual earnings growth rate forecast of more than eighteen% through 2024, more than double the biotech manufacture's projected earnings growth rate and also slightly higher than the U.S. market boilerplate earnings growth rate.

At a current cost of merely over $21 per share, Exelixis is at a very attainable entry betoken for new investors and shows a lot of growth potential. Nevertheless, it's worth noting that the price dropped recently when a Stage 3 trial for the company'southward renal jail cell carcinoma treatment was not shown to be as effective as the company hoped.

Pros:

Affordable stock
Potent buy rating from analysts

Cons:

Recent drug showed poor results in Phase iii trial
Not a curt-term buy

Bio-Techne

Bio-Techne is a bit different from the other firms on this list. Rather than developing drug treatments, information technology supplies biological materials to other pharmaceutical and biotech firms for drug development and testing. It is also i of just a few companies on this list to offering a dividend.

The visitor has a projected earnings growth of 17.32%, according to MarketBeat, whose analysts give it a "moderate buy" rating. 4 out of 5 Wall Street analysts rated Bio-Techne a "buy," with one giving information technology a "sell" rating.

As well, Zacks.com predicts an above average return from the stock relative to the marketplace in the coming months and that it is fairly valued correct now.

Pros:

Pays a dividend of 0.3%
Stiff buy rating from analysts

Cons:

Expensive entry point at just under $350

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is probably all-time known for its COVID-19 treatment, REGEN-COV, which was granted an Emergency Utilise Dominance by the FDA. That EUA was later retracted, however, when the handling was institute to exist ineffective against the Omicron variant.

However, the company stock maintains loftier ratings, with Kiplinger.com calling it "i of the best biotech stocks in terms of technical performance." The stock outperformed the iShares Biotechnology ETF by a broad margin between April 2021 and April 2022, and the stock continues its upward climb.

MarketBeat gave the stock a "moderate buy" rating, with 12 Wall Street analysts rating information technology a "buy," five giving information technology a "hold," and ii saying information technology is a "sell" now to cash in on the visitor's profitability from the past year. The stock has a projected earnings growth of v.59%, according to MarketBeat.

Pros:

Analysts give information technology a purchase rating
Solid projected earnings growth

Cons:

Expensive entry point of $600 or higher
No dividends

Final Take

Biotech stocks, peculiarly in a conduct market, can stand for a tremendous value to investors with a moderate to high risk-tolerance. To mitigate gamble, you might consider investing in a biotech ETF instead, like the iShares Biotechnology ETF (IBB) or the SPDR S&P Biotech ETF (XBI).

Biotech Stocks FAQ

Hither are some commonly asked questions regarding investing in biotech stocks.

Is information technology worth investing in biotech?
- Biotech stocks carry risks, as with whatsoever investments, but they tin show tremendous returns over time. Experts say that biotech stocks may be splendid long-term investments, in office because of the lengthy time-to-market for many drugs. If y'all want to diversify your risk, consider investing in a biotech ETF, which is a counterbalanced collection of biotech stocks.
What biotech stock did Warren Buffett buy?
- In 2019, Warren Buffett's investment firm Berkshire Hathaway purchased biotech stocks for the first time. The firm purchased more than 648,000 shares of Biogen stock, worth $192.four million. It was the first biotech visitor Buffett chose to invest in through his decades long history as the Oracle of Omaha. All the same, in an uncharacteristic move for the investor, he sold those shares in the second quarter of 2021, post-obit the FDA's controversial approval of Biogen'southward promising Alzheimer's drug. At the time, the stock may have been worth as much as $267 1000000, or a 39% render-on-investment if Buffett sold at the stock'south high point. In terms of biotech stock that Warren Buffett owns or has owned, Berkshire Hathaway has as well held positions in Merck, AbbVie, Pfizer and Bristol Myers Squibb.

Information is accurate as of July 13, 2022.

Dawn Allcot is a full-time freelance writer and content marketing specialist who geeks out about finance, e-commerce, technology, and real manor. Her lengthy list of publishing credits include Bankrate, Lending Tree, and Hunt Bank. She is the founder and owner of GeekTravelGuide.net, a travel, applied science, and entertainment website. She lives on Long Island, New York, with a veritable menagerie that includes 2 cats, a rambunctious kitten, and three lizards of varying sizes and personalities – plus her ii kids and hubby. Find her on Twitter, @DawnAllcot.

Newsletter background image